Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season

被引：21

作者：

Rondy, Marc ^{[1
]}

Gherasim, Alin ^{[2
,3
]}

Casado, Itziar ^{[3
,4
]}

Launay, Odile ^{[5
,6
]}

Rizzo, Caterina ^{[7
]}

Pitigoi, Daniela ^{[8
]}

Mickiene, Aukse ^{[9
]}

Marbus, Sierk D. ^{[10
]}

Machado, Ausenda ^{[11
]}

Syrjanen, Ritva K. ^{[12
]}

Pem-Novose, Iva ^{[13
]}

Horvath, Judith Krisztina ^{[14
]}

Larrauri, Amparo ^{[2
,3
]}

Castilla, Jesus ^{[3
,4
]}

Vanhems, Philippe ^{[5
,15
,16
]}

Alfonsi, Valeria ^{[7
]}

Ivanciuc, Alina E. ^{[17
]}

Kuliese, Monika ^{[9
]}

van Gageldonk-Lafeber, Rianne ^{[10
]}

Gomez, Veronica ^{[11
]}

Ikonen, Niina ^{[18
]}

Lovric, Zvjezdana ^{[13
]}

Ferenczi, Annamaria ^{[14
]}

Moren, Alain ^{[1
]}

机构：

[1] EpiConcept, Paris, France

[2] Inst Hlth Carlos III, Natl Ctr Epidemiol, Madrid, Spain

[3] Inst Hlth Carlos III, CIBER Epidemiol & Salud Publ, Madrid, Spain

[4] IdiSNA, Inst Salud Publ Navarra, Pamplona, Spain

[5] INSERM, F CRIN, Innovat Clin Res Network Vaccinol I REIVAC, CIC 1417, Paris, France

[6] Univ Paris 05, Sorbonne Paris Cite, CIC Cochin Pasteur, AP HP, Paris, France

[7] Ist Super Sanita, Rome, Italy

[8] Univ Med & Pharm Carol Davila, Natl Inst Res Cantacuzino, Bucharest, Romania

[9] Lithuanian Univ Hlth Sci, Dept Infect Dis, Kaunas, Lithuania

[10] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Ctr Epidemiol & Surveillance Infect Dis, Bilthoven, Netherlands

[11] Natl Hlth Inst Doutor Ricardo Jorge, Epidemiol Dept, Epidemiol Res Unit, Lisbon, Portugal

[12] Natl Inst Hlth & Welf, Impact Assessment Unit, Tampere, Finland

[13] Croatian Inst Publ Hlth, Epidemiol Serv, Zagreb, Croatia

[14] Off Chief Med Officer, Budapest, Hungary

[15] Hosp Civils Lyon, Hop Edouard Herriot, Infect Control & Epidemiol Unit, Lyon, France

[16] Univ Claude Bernard Lyon 1, Ecole Natl Super ENS Lyon, UMR5308,Emerging Pathogens Lab, CNRS,INSERM,U1111,Ctr Int Rech Infectiol,Fdn Meri, Lyon, France

[17] Univ Bucharest, Fac Biol, Natl Inst Res Cantacuzino, Bucharest, Romania

[18] Natl Inst Hlth & Welf, Unit Expert Microbiol, Helsinki, Finland

来源：

EUROSURVEILLANCE | 2017年 / 22卷 / 41期

关键词：

EUROPE;

D O I：

10.2807/1560-7917.ES.2017.22.41.17-00645

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those >= 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.

引用

页码：8 / 13

页数：6

共 9 条

[1]

European Centre for Disease Prevention and Control (ECDC), 2017, RISK ASS SEAS INFL

[2] Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe [J].